Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Total Liabilities (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Total Liabilities over the past 10 years, most recently at $35.2 million for Q4 2023.

  • For Q4 2023, Total Liabilities rose 5.57% year-over-year to $35.2 million; the TTM value through Dec 2023 reached $35.2 million, up 5.57%, while the annual FY2023 figure was $35.2 million, 5.57% up from the prior year.
  • Total Liabilities for Q4 2023 was $35.2 million at Corbus Pharmaceuticals Holdings, down from $36.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $66.6 million in Q3 2020 and troughed at $31.9 million in Q3 2022.
  • A 5-year average of $41.9 million and a median of $38.6 million in 2019 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 409.41% in 2019 and later plummeted 37.03% in 2021.
  • Year by year, Total Liabilities stood at $43.0 million in 2019, then surged by 32.65% to $57.0 million in 2020, then plummeted by 32.27% to $38.6 million in 2021, then dropped by 13.72% to $33.3 million in 2022, then grew by 5.57% to $35.2 million in 2023.
  • Business Quant data shows Total Liabilities for CRBP at $35.2 million in Q4 2023, $36.0 million in Q3 2023, and $34.2 million in Q2 2023.